Sugentech Inc (253840) Fair Value & Analysis
Healthcare · KR · Market cap 73.8B KRW
Fair value as of: Jun 25, 2026
Analysis
Sugentech Inc (253840) currently trades at 4,070 KRW, while our model-based Fair Value estimate is 2,223 KRW — implying the stock looks roughly 45.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Sugentech Inc (253840) undervalued?
What is the fair value of 253840?
What is the quality score of 253840?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.